Daniel Apel serves as Chief Financial Officer at Arrowhead Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing innovative RNA interference (RNAi) therapeutics for intractable diseases. With over two decades of experience in finance within the life sciences sector, Apel joined Arrowhead in 2016 as Vice President of Finance before ascending to CFO in 2018. A Certified Public Accountant (CPA), he previously spent more than a decade at PricewaterhouseCoopers (PwC), where he rose to Senior Manager in the Life Sciences audit practice, advising biotech and pharmaceutical clients on complex financial reporting, SEC compliance, and capital-raising strategies. Under Apel's leadership, Arrowhead has significantly strengthened its financial position, executing multiple equity offerings that raised over $1 billion to fund its expanding clinical pipeline, including late-stage programs in cardiovascular and liver diseases. His strategic oversight has been instrumental in navigating the company's transition from early-stage research to a robust portfolio of investigational therapies, while maintaining rigorous financial discipline amid volatile biotech markets. Apel's expertise in technical accounting and investor relations has enhanced Arrowhead's transparency and appeal to institutional investors. Apel's contributions extend beyond finance; he plays a key role in corporate development, supporting partnerships and licensing deals that have accelerated Arrowhead's growth. His deep industry knowledge and proven track record continue to position the company for long-term success in pioneering RNAi-based treatments.